文献速递慢性静脉疾病

超声引导泡沫硬化剂治疗大隐静脉与小隐静脉主干与慢性静脉疾病患者低5年复发率及生活质量改善相关:一项多中心研究

Ultrasound-guided foam sclerotherapy of the saphenous trunks is associated with a low 5-year recurrence rate and improved quality of life in patients with chronic venous disease: A multicenter study.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-02-19

这项多中心回顾性队列研究纳入346例原发性慢性静脉疾病(CEAP临床分级2-4级)患者,评估超声引导泡沫硬化剂(UGFS)治疗大隐静脉和小隐静脉主干功能不全的长期疗效。中位随访60个月,296例(85.5%)无主干反流,5年无病生存率为77.7±2.16%,90例(26%)复发,中位复发时间48个月。UGFS长期有效、安全且患者接受度好,可作为手术及腔内热消融或非热消融的可行选择。

要点

  • 中位随访60个月,296例(85.5%)无主干反流,5年无病生存率77.7±2.16%。
  • 主干直径≤8 mm者复发率低于>8 mm者(91.3% vs 46%,P<.0001)。
  • 大直径主干、男性及治疗次数多是复发的显著预后因素。

核心结论

  • UGFS治疗大隐静脉/小隐静脉主干功能不全是长期有效、安全且患者接受度好的方法。
  • UGFS是手术治疗及腔内热消融或非热消融治疗主干功能不全(CEAP临床分级2-4级)的可行选择。

研究设计与样本

  • 多中心回顾性队列研究,纳入346例原发性慢性静脉疾病(CEAP临床分级2-4级)患者。
  • 硬化剂为泡沫化十四烷基硫酸钠(STS),采用双注射器技术制备泡沫(液体与气体CO2O2比例30:70,即1:4)。
  • 静脉主干直径4-7 mm者STS浓度为1%,>7 mm者为3%,直接注入大隐静脉/小隐静脉,单次最大总剂量10 mL,中位治疗2次(范围1-5次)。
  • 中位随访60个月(范围6-60个月)。

主要发现

  • 随访结束时296例(85.5%)无主干反流,5年无病生存率(末次手术至复发证据之间)为77.7±2.16%。
  • 大隐静脉与小隐静脉5年无复发生存率相似(69.9% vs 76.8%,P=ns)。
  • 主干直径≤8 mm者复发率低于>8 mm者(91.3% vs 46%,P<.0001)。
  • 90例(26%)出现慢性静脉疾病复发,中位复发时间48个月;50例有症状患者(14.4%)需再次UGFS治疗,成功率为80%。
  • 单因素分析显示,主干大直径(P<.0001)、男性(P=.030)和治疗次数多(P=.009)是复发的显著预后因素。

关键数值与推荐

  • CEAP临床分级2级者205例(59.2%),CEAP≥3级者141例(40.8%)。
  • 即刻并发症发生率为3.7%:头痛7例、视觉障碍6例;治疗后1周检出静脉内泡沫诱导血栓形成6例(2.8%);皮肤色素沉着37例(10.7%)。

临床怎么用

  • 对于CEAP临床分级2-4级的大隐静脉/小隐静脉主干功能不全,UGFS可作为手术及腔内热消融或非热消融治疗的可行选择。
  • 主干直径≤8 mm者复发率低于>8 mm者(91.3% vs 46%,P<.0001),大直径主干、男性及治疗次数多者复发风险较高(单因素分析)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study attempts to test whether ultrasound-guided foam sclerotherapy (UGFS) is a durable treatment for incompetent great saphenous vein (GSV) and incompetent small saphenous vein (SSV) in primary chronic venous disease (CVD), Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical grade 2 to 4 disease. Secondary end points are to evaluate its safety in terms of complications, to compare patients' quality of life before and after the treatment, and to identify risk factors that may predict recurrence of CVD after UGFS. METHODS: Multicenter retrospective cohort study on 346 patients. The sclerosing agent was sodium tetradecyl sulfate (STS) in foam. The foam was prepared with the double-syringe technique (liquid-to-gas CO2O2 30:70 ratio of 1:4). The sclerosing agent concentrations were 1% for saphenous trunk diameter 4 to 7 mm, 3% for saphenous trunk of >7 mm. Sodium tetradecyl sulfate was injected directly into the GSV/SSV, achieving a total maximum volume of 10 mL per session. A median of two sessions was performed (range, 1-5). RESULTS: In this cohort, 205 patients were categorized as CEAP C2 (59.2%), and 141 (40.8%) had worse CVD (CEAP ≥3). The median follow-up was 60 months (range, 6-60 months). At the end of follow-up, 296 patients (85.5%) had no truncal reflux, with a 5-year disease-free time (between last procedure and evidence of recurrent disease) of 77.7 ± 2.16%. GSV and SSV showed similar 5-year recurrence-free time rates (69.9% vs 76.8%; P = ns), whereas patients with a diameter of the saphenous trunk of ≤8 mm had lower recurrence than those with >8 mm (91.3% vs 46%; P < .0001). Ninety patients (26%) showed CVD recurrence, occurring at a median of 48 months. A further UGFS treatment was needed in 50 symptomatic patients (14.4%), resulting in an 80% success rate. At univariate analysis, large diameter of the saphenous trunk (P < .0001), male sex (P = .030) and greater number of treatment sessions (P = .009) were identified as significant prognostic factors for recurrence. Immediate complications occurred in 3.7% of patients: seven headache and six visual disturbances. Endovenous foam-induced thrombosis was detected in six patients (2.8%) 1 week after treatment. Cutaneous hyperpigmentation appeared in 37 patients (10.7%). Post-treatment revised Venous Clinical Severity Score and Chronic Venous Disease Quality of Life Questionnaire 14 scores were significantly lower than before treatment (P < .001). CONCLUSIONS: UGFS of the GSV/SSV is effective, safe in the long term and well-accepted by patients. UGFS is a viable option to surgery and endovenous thermal or nonthermal ablation in the treatment of saphenous trunk incompetence (CEAP clinical grade 2-4).

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Mariani F, Carbone L, Sozio G, et al. Ultrasound-guided foam sclerotherapy of the saphenous trunks is associated with a low 5-year recurrence rate and improved quality of life in patients with chronic venous disease: A multicenter study. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 39983866. doi:10.1016/j.jvsv.2025.102212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。